From Yahoo Finance: 2025-06-12 18:37:00

Insmed Inc. (NASDAQ:INSM) stock soared by 7.75 percent after announcing plans to raise $650 million through the issuance of more shares. The funds will be used for research and development of drug candidates like brensocatib and Arikayce. The company also achieved positive results in a phase 2 trial for its PAH treatment, TPIP.

Following the fundraising announcement, four investment companies gave Insmed a “buy” recommendation with price targets from $102 to $110. Insmed ranks 10th on a list of best-performing stocks. While it shows promise, some AI stocks may offer higher returns with less risk.

Insmed Inc. (NASDAQ:INSM) granted underwriters the option to purchase an additional $97.5 million of its common stock. This move follows the successful phase 2 trial of its pulmonary arterial hypertension treatment, TPIP, which met primary and secondary goals.

Overall, Insmed Inc. (NASDAQ:INSM) continues to gain attention from investors and analysts after raising $650 million through a stock issuance. The company aims to use the funds for further research and development of its promising drug candidates and potential business expansion.



Read more at Yahoo Finance: Insmed (INSM) Soars After Raising $650 million